Publications by authors named "K Gallacher"
Background: Digital Health (DH) integrates digital technologies into healthcare to increase efficiency and improve patient experiences, benefiting both primary care and military healthcare systems. However, it raises concerns about the potential shift of healthcare responsibilities onto patients, creating workloads or treatment burdens that affect care, adherence, equity, and resource allocation. It is critical to assess this in the military context to enhance patient-centred care and outcomes.
View Article and Find Full Text PDFIntroduction: Clinical guidelines recommend the use of the kidney failure risk equation (KFRE) to guide the referral of individuals with chronic kidney disease (CKD) to secondary kidney care services. People living with CKD frequently experience multiple long-term conditions (multimorbidity) and/or frailty. This may impact patients' or carers' perceptions of kidney failure in the context of other health problems and associated risks and emphasises the need for shared decision-making.
View Article and Find Full Text PDFArticle Synopsis
- Prognostic models for chronic kidney disease (CKD) are essential for identifying at-risk patients and enabling precision medicine, but they often fail to consider multimorbidity and frailty.
- A systematic review found that out of 97 studies on kidney failure models, only a few reported on multimorbidity and none adequately included frailty in their assessments.
- The lack of studies addressing these factors limits the evidence-based guidance for treating patients with CKD who have multiple health issues, highlighting a critical area for future research.
Purpose: Prioritisation exercises seek out what matters to key stakeholders to inform the planning of research. Social media platforms are potentially useful data sources. The aim was to examine the content of tweets, short messages containing text and pictures, to ascertain the priorities of Twitter users regarding stroke recovery.
View Article and Find Full Text PDFArticle Synopsis
- About 50% of neuroblastomas with poor prognosis are linked to the over-expression of the MYCN protein, and previous research has shown that targeting PRMT5 leads to cell death in these cases.
- The study evaluates GSK3203591, a new PRMT5 inhibitor, showing that it inhibits MYCN-dependent growth and triggers changes in gene expression and mRNA splicing in MNA neuroblastoma cells, particularly affecting glutamine metabolism.
- In tests on mice, the related compound GSK3326593 demonstrated increased survival, confirming that both drugs exploit PRMT5's role in splicing and regulation of metabolic pathways in MYCN-amplified neuroblastomas.